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1. INTRODUCTION {#clc23220-sec-0001}
===============

In November 2018, results of the REDUCE‐IT (Reduction of Cardiovascular Events with EPA‐Intervention Trial) trial were published.[1](#clc23220-bib-0001){ref-type="ref"} The trial demonstrated that treatment with a high dose (4 g per day) of the omega‐3 polyunsaturated fatty acid (PUFA) icosapent ethyl significantly reduced the risk of ischemic cardiovascular (CV) events and CV death in patients who (a) were on a stable dose of statin, (b) had established CV disease or type 2 diabetes mellitus and at least one additional CV risk factor, and (c) had elevated triglyceride (TG) levels at baseline (\>135 or 150 mg/dL). These results were remarkable because they followed a series of major TG‐lowering trials that had failed to achieve reductions in CV outcomes in similar groups of patients.[2](#clc23220-bib-0002){ref-type="ref"}, [3](#clc23220-bib-0003){ref-type="ref"}, [4](#clc23220-bib-0004){ref-type="ref"}, [5](#clc23220-bib-0005){ref-type="ref"}, [6](#clc23220-bib-0006){ref-type="ref"} Why was REDUCE‐IT different? Are the results due solely to lowering of TG levels? What do the results mean for prevention of CV events in patients with established CV disease and elevated TG levels?

2. RESIDUAL RISK {#clc23220-sec-0002}
================

In recent decades, statins have become the mainstay of lipid‐lowering therapy to reduce risk of CV events in patients with atherosclerotic cardiovascular disease (ASCVD).[5](#clc23220-bib-0005){ref-type="ref"} Statin therapy, which primarily targets low‐density lipoprotein cholesterol (LDL‐C), has a firmly established role in reducing the risk of CV events by 25% to 35% in such patients.[5](#clc23220-bib-0005){ref-type="ref"} The reduction in risk is related to the absolute reduction in LDL‐C levels.[7](#clc23220-bib-0007){ref-type="ref"} However, despite successful lowering of LDL‐C levels with statins, patients with ASCVD remain at elevated risk of CV events.[8](#clc23220-bib-0008){ref-type="ref"} PCSK9 (proprotein convertase subtilisin‐kexin type 9) inhibitors further reduce LDL‐C levels and CV event rates, but excess CV risk persists (eg, 3‐year event rates of approximately 10‐13 percent) even in patients with median LDL‐C levels of 30 to 40 mg/dL achieved with the combination of a statin and a PCSK9 inhibitor.[9](#clc23220-bib-0009){ref-type="ref"}, [10](#clc23220-bib-0010){ref-type="ref"} Although non‐lipid‐related factors---such as smoking, obesity, and diabetes mellitus---account for some of this residual risk,[8](#clc23220-bib-0008){ref-type="ref"} elevated TG levels or low high‐density lipoprotein cholesterol (HDL‐C) levels have been suspected, since they have been shown to be markers of residual risk in analyses of data from several large statin trials.[11](#clc23220-bib-0011){ref-type="ref"}, [12](#clc23220-bib-0012){ref-type="ref"}, [13](#clc23220-bib-0013){ref-type="ref"}, [14](#clc23220-bib-0014){ref-type="ref"}, [15](#clc23220-bib-0015){ref-type="ref"} Other lipid and lipoprotein fractions---such as non‐HDL‐C, apolipoprotein B, and LDL particle number---are also markers of residual risk.[16](#clc23220-bib-0016){ref-type="ref"}

There is a strong inverse relationship between TG levels and HDL‐C levels; individuals with low HDL‐C levels generally have elevated TG levels and vice versa.[17](#clc23220-bib-0017){ref-type="ref"} However, because observational studies have consistently found a link between low HDL‐C and CV risk,[18](#clc23220-bib-0018){ref-type="ref"}, [19](#clc23220-bib-0019){ref-type="ref"}, [20](#clc23220-bib-0020){ref-type="ref"}, [21](#clc23220-bib-0021){ref-type="ref"}, [22](#clc23220-bib-0022){ref-type="ref"}, [23](#clc23220-bib-0023){ref-type="ref"} several clinical trials were conducted in an effort to reduce CV risk by administering treatments intended to increase HDL‐C levels.[24](#clc23220-bib-0024){ref-type="ref"}, [25](#clc23220-bib-0025){ref-type="ref"}, [26](#clc23220-bib-0026){ref-type="ref"}, [27](#clc23220-bib-0027){ref-type="ref"}, [28](#clc23220-bib-0028){ref-type="ref"} Although the treatments substantially increased HDL‐C levels, only one trial reported a small decrease in major CV event rates, and that decrease was consistent with the degree of LDL‐C lowering.[28](#clc23220-bib-0028){ref-type="ref"} We now have a better understanding of why efforts to increase HDL‐C levels have had such limited success in reducing CV event rates; recent studies using the method of Mendelian randomization (MR) have supported the conclusion that low HDL‐C is *not causally* associated with increased CV risk.[29](#clc23220-bib-0029){ref-type="ref"}, [30](#clc23220-bib-0030){ref-type="ref"}, [31](#clc23220-bib-0031){ref-type="ref"} These studies have revealed that genetic variants influencing HDL‐C levels do not significantly affect CV risk. Thus, although a low HDL‐C level is a marker of increased CV risk, there is now a strong body of evidence from both clinical trials and MR studies that a low HDL‐C level is *not causally* related to an increased risk of CV events.[32](#clc23220-bib-0032){ref-type="ref"}

During the era just described, TG re‐emerged as an independent CV risk factor. As recently as 2011, a scientific statement from the American Heart Association concluded that the role of TG as an independent causal factor for CV disease was "debatable."[17](#clc23220-bib-0017){ref-type="ref"} Subsequently, MR studies provided strong evidence that elevated TG‐rich lipoproteins (TRLs) *are causally* related to increased risk for CV events.[30](#clc23220-bib-0030){ref-type="ref"}, [32](#clc23220-bib-0032){ref-type="ref"}, [33](#clc23220-bib-0033){ref-type="ref"}, [34](#clc23220-bib-0034){ref-type="ref"}, [35](#clc23220-bib-0035){ref-type="ref"}, [36](#clc23220-bib-0036){ref-type="ref"} Furthermore, analyses of statin trials have found that patients with elevated TG levels after statin therapy are at particularly high risk for CV events. Thus, even though statins (as well as ezetimibe and PCSK9 inhibitors) reduce TG levels along with lowering LDL‐C,[37](#clc23220-bib-0037){ref-type="ref"} some patients continue to have elevated TG levels, which is now recognized as a risk factor for CV events. These developments have re‐invigorated research efforts to identify and develop strategies to reduce TG levels and TRLs.[38](#clc23220-bib-0038){ref-type="ref"}

Several diet and lifestyle interventions---including weight loss, physical activity, moderation of alcohol consumption, and Mediterranean‐style diet---are recommended for reducing elevated TG levels.[17](#clc23220-bib-0017){ref-type="ref"} The mainstays of TG‐lowering pharmacotherapies had been fibrates and niacin, despite the fact that these agents had very little success in lowering CV risk. More recently, attention has turned to the omega‐3 fatty acids eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA), which are found in high concentrations in oily fishes and are known to reduce blood TG levels.[39](#clc23220-bib-0039){ref-type="ref"}, [40](#clc23220-bib-0040){ref-type="ref"} Indeed, low consumption of EPA and DHA has been associated with increased risk for CV disease in some observational studies.[40](#clc23220-bib-0040){ref-type="ref"} Beyond their effects on TG levels, omega‐3 PUFAs have numerous biological effects that may influence CV risk. Therefore, before discussing clinical trials of omega‐3 PUFAs for CV risk reduction, we will briefly review the biology of EPA and DHA.

2.1. EPA and DHA: TG lowering and beyond {#clc23220-sec-0003}
----------------------------------------

Essential fatty acids are those fats that cannot be synthesized by humans; they must be consumed. The two essential fatty acids in the human diet are linoleic acid (LA; an omega‐6 FA) and alpha‐linolenic acid (ALA; an omega‐3 PUFA).[41](#clc23220-bib-0041){ref-type="ref"} LA is the precursor for arachidonic acid, and ALA is the precursor for EPA (and minimally DHA).[42](#clc23220-bib-0042){ref-type="ref"} The main dietary sources of ALA are plants and plant products (such as vegetable oils). In theory, humans possess enzymes necessary to synthesize EPA and DHA from plant‐based ALA. In reality, the production of EPA and DHA from ALA is inconsequential. Making matters worse, omega‐6 PUFAs, which are often overly abundant in the western diet, dampen the conversion of ALA to EPA and DHA.[42](#clc23220-bib-0042){ref-type="ref"}, [43](#clc23220-bib-0043){ref-type="ref"} Thus, many experts consider EPA and DHA to be essential fatty acids.[43](#clc23220-bib-0043){ref-type="ref"}

Key dietary sources of EPA and DHA are oily fishes,[42](#clc23220-bib-0042){ref-type="ref"} and several epidemiologic studies have found that groups of people who consume large amounts of such fish have lower rates of CV events and CV death compared with other populations (reviewed in Nishizaki et al.[44](#clc23220-bib-0044){ref-type="ref"}). Other studies, however, did not find a significant protective effect from consumption of a diet high in fish or EPA or DHA.[45](#clc23220-bib-0045){ref-type="ref"} These studies varied widely with regard to the amount and types of PUFAs consumed by the study population. In 2006, a pooled analysis of prospective studies and randomized trials concluded that consumption of fish or fish oil was associated with a 36% reduction in the relative risk of death from coronary heart disease.[46](#clc23220-bib-0046){ref-type="ref"} Thus, at that time, the prevailing medical opinion was that omega‐3 PUFAs from fish had a favorable effect on CV outcomes.

Further support for a role of EPA and DHA in CV risk reduction came from biomarker studies. A pooled analysis of cohort studies conducted around the world found that higher levels of plasma or phospholipid omega‐3 PUFAs (EPA, DHA, docosapentaenoic acid \[DPA\], and plant‐derived ALA) were associated with a modest (approximately 10%) but significantly lower risk of fatal CHD.[47](#clc23220-bib-0047){ref-type="ref"} When evaluating both observational and interventional studies of omega‐3 PUFAs, it is important, however, to consider whether the investigators have distinguished ALA, EPA, and, DHA. We now understand that there are substantial differences in their biological activities.[48](#clc23220-bib-0048){ref-type="ref"} Thus, studies that combine the omega‐3 PUFAs may fail to discern important health effects that are mostly due to one particular omega‐3 PUFA.

Studies have consistently found that fish‐oil consumption, as well as consumption of purified EPA or DHA, robustly reduce serum TG levels.[49](#clc23220-bib-0049){ref-type="ref"}, [50](#clc23220-bib-0050){ref-type="ref"}, [51](#clc23220-bib-0051){ref-type="ref"}, [52](#clc23220-bib-0052){ref-type="ref"}, [53](#clc23220-bib-0053){ref-type="ref"} ALA, in contrast, has only small and inconsistent effects on TG levels.[49](#clc23220-bib-0049){ref-type="ref"}, [50](#clc23220-bib-0050){ref-type="ref"} In most of the studies that found TG‐lowering effects of fish oil (or EPA/DHA), participants received 1 g to \>4 g of the respective fatty acid per day.[52](#clc23220-bib-0052){ref-type="ref"} The TG lowering effect is linearly dose‐dependent, and individuals with higher baseline TG levels exhibit greater declines in absolute TG levels in response to omega‐3 PUFA consumption.[40](#clc23220-bib-0040){ref-type="ref"}

Reported biological actions of EPA and DHA extend well beyond TG lowering and include effects expected to be cardioprotective.[48](#clc23220-bib-0048){ref-type="ref"}, [54](#clc23220-bib-0054){ref-type="ref"}, [55](#clc23220-bib-0055){ref-type="ref"}, [56](#clc23220-bib-0056){ref-type="ref"}, [57](#clc23220-bib-0057){ref-type="ref"} As summarized by Mozaffarian and Rimm,[46](#clc23220-bib-0046){ref-type="ref"} and shown in Figure [1](#clc23220-fig-0001){ref-type="fig"}, fish oil omega‐3 PUFAs have been linked with reduced blood pressure and heart rate, as well as decreased platelet aggregation.[40](#clc23220-bib-0040){ref-type="ref"}, [58](#clc23220-bib-0058){ref-type="ref"}, [59](#clc23220-bib-0059){ref-type="ref"}, [60](#clc23220-bib-0060){ref-type="ref"}, [61](#clc23220-bib-0061){ref-type="ref"} They have also been linked with anti‐inflammatory actions and stabilization of coronary plaque.[62](#clc23220-bib-0062){ref-type="ref"}, [63](#clc23220-bib-0063){ref-type="ref"}, [64](#clc23220-bib-0064){ref-type="ref"}, [65](#clc23220-bib-0065){ref-type="ref"} Anti‐dysrhythmic actions have been observed in animal or cell models, but their significance in humans is controversial.[40](#clc23220-bib-0040){ref-type="ref"} As shown in Figure [1](#clc23220-fig-0001){ref-type="fig"}, some of the observed cardioprotective effects of omega‐3 PUFAs require comparatively high doses of EPA/DHA; for example, lowering of diastolic blood pressure seems to require doses of ≥2 g per day,[59](#clc23220-bib-0059){ref-type="ref"} and antithrombotic effects appear to require even higher doses.[66](#clc23220-bib-0066){ref-type="ref"} It is plausible that other biological effects of omega‐3 PUFAs---such as contributions to the mediation of inflammation[67](#clc23220-bib-0067){ref-type="ref"}, [68](#clc23220-bib-0068){ref-type="ref"}---may contribute to improvements in CV endpoints, although those relationships need extensive additional testing.

![Conceptual depiction of the effects of fish‐derived omega‐3 polyunsaturated fatty acids on cardiovascular risk factors, including estimated dose dependence. Dose dependence was estimated from analyses of multiple studies of each risk factor. Modified from Mozaffarian and Rimm,[46](#clc23220-bib-0046){ref-type="ref"} used with permission](CLC-42-829-g001){#clc23220-fig-0001}

3. RANDOMIZED CONTROLLED TRIALS AND META‐ANALYSES {#clc23220-sec-0004}
=================================================

Large‐scale, randomized trials have examined three classes of treatments targeting TG levels: fibrates, niacin, and omega‐3 PUFAs. These trials have been thoroughly discussed by other recent reviews,[5](#clc23220-bib-0005){ref-type="ref"}, [17](#clc23220-bib-0017){ref-type="ref"}, [44](#clc23220-bib-0044){ref-type="ref"}, [69](#clc23220-bib-0069){ref-type="ref"} so we will briefly summarize the state of the field up to 2018. Then we will discuss very recent studies, including three trials of omega‐3 PUFAs that were published in 2018.

3.1. Fibrates and niacin {#clc23220-sec-0005}
------------------------

As noted by prior reviews,[5](#clc23220-bib-0005){ref-type="ref"}, [70](#clc23220-bib-0070){ref-type="ref"} trials of fibrates or niacin added to statin therapy have failed to show a benefit of the added treatment in terms of CV event rates.[12](#clc23220-bib-0012){ref-type="ref"}, [25](#clc23220-bib-0025){ref-type="ref"}, [26](#clc23220-bib-0026){ref-type="ref"}, [71](#clc23220-bib-0071){ref-type="ref"}, [72](#clc23220-bib-0072){ref-type="ref"} The ongoing PROMINENT trial, involving the novel fibrate pemafibrate,[73](#clc23220-bib-0073){ref-type="ref"} may provide insight into this question (NCT03071692).

3.2. Fish oil omega‐3 PUFAs: Background of clinical studies {#clc23220-sec-0006}
-----------------------------------------------------------

A 2011 review analyzed randomized controlled trials, prospective cohort studies, and meta‐analyses conducted up to that time and concluded that consumption of fish or fish oil reduced coronary heart disease mortality in populations with and without established CV disease.[40](#clc23220-bib-0040){ref-type="ref"} Three meta‐analyses of randomized controlled trials of omega‐3 PUFA supplements supported this conclusion.[46](#clc23220-bib-0046){ref-type="ref"}, [74](#clc23220-bib-0074){ref-type="ref"}, [75](#clc23220-bib-0075){ref-type="ref"} However, another meta‐analysis of randomized controlled trials published in 2012 concluded that omega‐3 PUFA supplementation was not associated with significant reduction in the risk of all‐cause death, cardiac death, or myocardial infarction.[76](#clc23220-bib-0076){ref-type="ref"} That meta‐analysis, however, used an unusually high threshold for statistical significance (*α* = 0.0063). It is remarkable, for example, that all 17 of the trials included in the analysis of all‐cause death reported a relative risk \<0.96 favoring omega‐3 PUFA, and seven of those trials reported upper confidence intervals that were \< 1.0, yet the meta‐analysis failed to find a significant benefit of omega‐3 PUFAs for all‐cause death. The authors noted that there was extensive heterogeneity across trials with regard to event rates, baseline CV disease risk, treatment setting (eg, primary prevention vs secondary prevention), co‐administered therapies, baseline intake of omega‐3 PUFAs, dose, and nature of omega‐3 PUFA used for the intervention, and treatment adherence. Thus, heterogeneity was likely so high that a meaningful conclusion could not be reached. A more recent meta‐analysis revealed the importance of such heterogeneity. That study[77](#clc23220-bib-0077){ref-type="ref"} also found a non‐significant reduction in coronary heart disease risk across the entire study group (summary relative risk estimate \[SSRE\], 0.94; 95% CI 0.85‐1.05), but it found that high‐risk populations obtained significant benefits from omega‐3 PUFA interventions. Specifically, patients with elevated baseline TG levels had an SSRE of 0.86 (95% CI 0.76‐0.98). The authors also found evidence that higher intakes of omega‐3 PUFAs were associated with significantly greater reductions in coronary heart disease risk (SSRE, 0.82; 95% CI 0.74‐0.92). These meta‐analyses reinforce the importance of trial design; patient subgroups should be carefully and prospectively defined and studied in clinical trials, and doses and compositions of omega‐3 PUFAs need to be precisely constructed and controlled.

3.3. Fish oil omega‐3 PUFAs: Recent trials {#clc23220-sec-0007}
------------------------------------------

In 2018, the results of two major trials (ASCEND and VITAL) of omega‐3 PUFA (1 g per day) for *primary* prevention of CV disease were reported.[4](#clc23220-bib-0004){ref-type="ref"}, [78](#clc23220-bib-0078){ref-type="ref"} Neither trial reported a significant reduction in the risk of a composite cardiovascular endpoint in the omega‐3 PUFA group compared to the placebo group, although the VITAL trial reported a significantly lower rate of myocardial infarction in the omega‐3 PUFA arm. Both trials excluded patients with established CV disease, and neither trial required statin therapy or enrolled patients on the basis of elevated TG levels. As discussed in more detail below, both trials may have used inadequate doses of omega‐3 PUFAs. Another possibility is that the trial population was at too low risk to reveal statistically significant benefits of omega‐3 PUFAs. A third major trial reported in 2018 (REDUCE‐IT) studied an omega‐3 PUFA in patients with established CV disease or diabetes mellitus and at least one additional CV risk factor.[1](#clc23220-bib-0001){ref-type="ref"} In addition, participants were required to be on a stable dose of statin and to have an elevated fasting TG level (150‐499 mg/dL). The trial enrolled 8179 patients (71% of whom had established CV disease) and randomized them to icosapent ethyl (a purified and stable ethyl ester of EPA; 2 g twice daily) or placebo. The primary endpoint was a composite of cardiovascular death, MI, stroke, coronary revascularization, or unstable angina. After a median follow‐up of 4.9 years, the icosapent ethyl group had a significantly lower rate of primary endpoint events (17.2% of patients) compared to the placebo group (22.0%; HR, 0.75; 95% CI, 0.68‐0.83; *P* = .001). A similar benefit of icosapent ethyl was found for the secondary endpoint of CV death, MI, and stroke (HR, 0.74; 95% CI, 0.65‐0.83; *P* \< .001). The benefits of icosapent ethyl were observed across a broad set of patient subgroups based on baseline characteristics, including TG and LDL‐C levels and the presence or absence of diabetes mellitus. It is important to note that all study participants had elevated TG levels at baseline (most \>150 mg/dL).

In the ASCEND and VITAL trials, there were no significant differences between active treatment groups and the placebo groups with regard to rates of non‐fatal serious adverse events, including bleeding.[4](#clc23220-bib-0004){ref-type="ref"}, [78](#clc23220-bib-0078){ref-type="ref"} In REDUCE‐IT, icosapent ethyl was associated with a small but significant increase in rates of hospitalization for atrial fibrillation or flutter vs placebo (3.1% vs 2.1%; *P* = .004) and a trend toward increased rates of serious bleeding (2.7% vs 2.1%; *P* = .06).[1](#clc23220-bib-0001){ref-type="ref"} However, prior reviews of bleeding risk associated with pharmacotherapeutic use of omega‐3 PUFAs (at daily doses of 1‐6 g) concluded that there was no effect on the risk of clinically significant bleeding.[79](#clc23220-bib-0079){ref-type="ref"}, [80](#clc23220-bib-0080){ref-type="ref"}

4. WAS REDUCE‐IT DIFFERENT? {#clc23220-sec-0008}
===========================

At first glance, it may seem that the results of REDUCE‐IT are at odds with those from prior trials of omega‐3 PUFAs. On closer inspection, it becomes evident that the results of REDUCE‐IT are consistent with observations from several previous studies. As already discussed, the most recent meta‐analysis of omega‐3 PUFA supplements for reducing the risk of CV events found that high‐risk patients, especially those with elevated TG levels, were more likely to obtain benefit from omega‐3 PUFA treatment.[77](#clc23220-bib-0077){ref-type="ref"} Similarly, a previous open‐label trial in Japan (JELIS, Japan EPA Lipid Intervention Study) found that icosapent ethyl (1.8 g per day) significantly reduced the risk of major coronary events in hypercholesterolemic patients (HR, 0.81; 95% CI 0.69‐0.95). Notably, patients in JELIS with elevated TG (≥150 mg/dL) and low HDL‐C levels (\<40 mg/dL) had the highest risk of coronary events and the greatest reduction in event rates associated with icosapent ethyl treatment (HR, 0.47; 95% CI, 0.23‐0.98; *P* = .043). Similar results were found in subgroup analyses of REDUCE‐IT: patients who had the combination of baseline TG ≥150 mg/dL and baseline HDL‐C ≤ 35 mg/dL exhibited a HR for the primary endpoint of 0.62 (icosapant ethyl group vs placebo group; 95% CI, 0.51‐0.77). The corresponding HR for patients who did not meet those baseline criteria was 0.79 (95% CI, 0.71‐0.88; *P* = .04 for subgroup‐by‐treatment interaction). Independent confirmation of the importance of those baseline criteria may be needed to fully understand their clinical implications.

Table [1](#clc23220-tbl-0001){ref-type="table"} presents a summary of the characteristics of major CV prevention trials of omega‐3 PUFAs, including the latest, REDUCE‐IT. Of these nine trials, only three---GISSI‐P, JELIS, and REDUCE‐IT---demonstrated significantly lower rates of the primary endpoint among patients in the omega‐3 PUFA group vs placebo. Notably, median baseline TG levels among participants of REDUCE‐IT (216 mg/dL) were substantially higher than in all other omega‐3 PUFA trials, with the other two positive trials having the second‐ and third‐highest baseline TG levels. REDUCE‐IT was the only omega‐3 PUFA trial that specifically required elevated TG levels at baseline. This prerequisite may be an important aspect of the trial\'s success. Observations from these studies suggest that elevated TG levels may be a marker for secondary CV prevention patients who are most likely to benefit from omega‐3 PUFA treatment.

###### 

Summary characteristics and results of major cardiovascular prevention trials of omega‐3 PUFAs

  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
                                    GISSI‐P[80](#clc23220-bib-0080){ref-type="ref"}   JELIS[81](#clc23220-bib-0081){ref-type="ref"}   GISSI‐HF[82](#clc23220-bib-0082){ref-type="ref"}                  OMEGA[83](#clc23220-bib-0083){ref-type="ref"}   Alpha‐Omega[2](#clc23220-bib-0002){ref-type="ref"}                       SU.FOL.OM3[84](#clc23220-bib-0084){ref-type="ref"}   ORIGIN[3](#clc23220-bib-0003){ref-type="ref"}                                   Risk and Prevention[85](#clc23220-bib-0085){ref-type="ref"}   VITAL[73](#clc23220-bib-0073){ref-type="ref"}   ASCEND[4](#clc23220-bib-0004){ref-type="ref"}                                  REDUCE‐IT[1](#clc23220-bib-0001){ref-type="ref"}
  --------------------------------- ------------------------------------------------- ----------------------------------------------- ----------------------------------------------------------------- ----------------------------------------------- ------------------------------------------------------------------------ ---------------------------------------------------- ------------------------------------------------------------------------------- ------------------------------------------------------------- ----------------------------------------------- ------------------------------------------------------------------------------ ----------------------------------------------------------
  Publication date                  1999                                              2007                                            2008                                                              2010                                            2010                                                                     2010                                                 2012                                                                            2013                                                          2018                                            2018                                                                           2018

  N                                 11 324                                            18 645                                          6975                                                              3851                                            4837                                                                     2501                                                 12 536                                                                          12 513                                                        25 871                                          15 480                                                                         8179

  Median follow‐up, years           3.5                                               4.6                                             3.9                                                               1 (treatment duration)                          3.3                                                                      4.7                                                  6.2                                                                             5                                                             5.3                                             7.4                                                                            4.9

  Enrollment Criteria                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              

  Primary or secondary prevention   Secondary                                         Primary                                         Secondary                                                         Secondary                                       Secondary                                                                Secondary                                            Primary                                                                         Mixed                                                         Primary                                         Primary                                                                        Mixed

  Enrollment criteria               Recent MI (≤3 months)                             Total‐C ≥ 251 mg/dL                             Chronic HF, NYHA classes II‐IV                                    Recent MI (≤14 days)                            Prior MI                                                                 History of MI, UA, or ischemic stroke                High risk + impaired fasting glucose, impaired glucose tolerance, or diabetes   ASCVD but no MI, or multiple risk factors                     Men ≥50 years; Women ≥55 years                  Diabetes mellitus, no evidence of CV disease                                   • Established CV disease (at least 70% of participants)\
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   • DM + other risk factors

  Baseline TG levels, mg/dL         No enrollment requirement                         135‐499                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      

  Baseline LDL, mg/dL               No requirement                                    ≥170                                            No enrollment requirement                                         41‐100                                                                                                                                                                                                                                                                                                                                                                                                                                                     

  Baseline statin required          No                                                Yes                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          

  Baseline lipid characteristics                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   

  Median TG mg/dL                   162‐163                                           153‐154                                         126                                                               NR                                              144‐150                                                                  97‐115                                               140‐142                                                                         150                                                           NR                                              NR                                                                             216

  Mean or median, HDL‐C, mg/dL      41                                                58‐59                                           NR                                                                NR                                              \~50                                                                     43                                                   46                                                                              51                                                            NR                                              49                                                                             40

  Mean or median, LDL‐C mg/dL       137‐138                                           182                                             NR                                                                \~49% had "hypercholesterolemia"                98‐102                                                                   2.6‐2.7                                              112                                                                             132‐133                                                       NR                                              112‐113 (non‐HDL‐C)                                                            75

  Lipid lowering therapy, %         \~5                                               100%, added to both arms                        22‐23                                                                                                             86                                                                       83‐87                                                53‐55                                                                           41                                                            38                                              75‐76                                                                          100

  Treatment                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        

  Active treatment (daily dose)     850 mg, EPA + DHA                                 1800 mg Icosapent ethyl                         850 mg, EPA + DHA                                                 460 mg EPA + 380 mg DHA                         Margarine containing ALA, EPA, and DHA (Avg 376 mg, EPA + DHA per day)   600 mg, EPA + DHA (2:1)                              465 mg EPA 375 mg DHA                                                           850 mg, EPA + DHA                                             460 mg EPA + 380 mg DHA (+/− vitamin D)         460 mg EPA + 380 mg DHA                                                        4 g Icosapent ethyl

  Primary endpoint                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 

  Primary endpoint                  Death, MI, or stroke                              Cardiac death, MI, UA, PCI, CABG                Co‐primary: Death, and Death or CV hospitalization                Sudden cardiac death                            CV event (fatal or nonfatal), PCI, or CABG                               CV death, MI, stroke                                 CV death                                                                        CV death or CV hospitalization                                MI, stroke or CV death                          First MI, stroke, TIA, or vascular death (excluding intracranial hemorrhage)   CV death, MI, stroke, coronary revascularization, UA

  Result, HR (95% CI)               0.85 (0.74‐0.98) 4‐way analysis                   0.81 (0.69--0.95)                               Death: 0.91 (0.833‐0.998), death or CV Hosp: 0.92 (0.849‐0.999)   0.95 (0.56‐1.60)                                1.01 (0.87‐1.17)                                                         1.08 (0.79‐1.47)                                     0.98 (0.87‐1.10)                                                                0.97 (0.88‐1.08)                                                                                              0.97 (0.87‐1.08)                                                               0.75(0.68--0.83)
  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Abbreviations: ALA, alpha‐linolenic acid; CABG, coronary artery bypass graft; CI, confidence interval; CV, cardiovascular; DHA, docosahexaenoic acid; EPA, eicosapentaenoic acid; HF, heart failure; HR, hazard ratio; MI, myocardial infarction; NR, not reported; PCI, percutaneous coronary intervention; UA, unstable angina.

Source: Modified and updated from Ganda et al.[5](#clc23220-bib-0005){ref-type="ref"} and Bhatt et al..[65](#clc23220-bib-0065){ref-type="ref"}

Another salient distinction between REDUCE‐IT and prior trials was the dose of omega‐3 PUFA administered during the treatment period (4 g per day vs ≤850 mg per day in other large trials other than JELIS). The efficacy of high‐dose omega‐3 PUFA in REDUCE‐IT is understandable in the context of JELIS and a recent meta‐analysis, which found that higher intakes of omega‐3 PUFAs were associated with greater risk reductions.[77](#clc23220-bib-0077){ref-type="ref"} Median plasma levels of EPA among participants in the REDUCE‐IT trial in the icosapent ethyl arm were 26.1 μg/mL at baseline and 144 μg/mL after 1 year. In JELIS, EPA levels were substantially higher at baseline (93‐97 μg/mL) and increased to approximately 165 /mL during icosapent ethyl treatment.[81](#clc23220-bib-0081){ref-type="ref"} Furthermore, in JELIS, the hazard ratio for CV events was inversely related to plasma EPA concentrations, with notable declines in hazard ratios observed when plasma EPA concentrations exceeded 100‐150 μg/mL. Unfortunately, very few past trials of omega‐3 PUFAs have measured baseline or on‐treatment plasma EPA levels. It is important to recognize that the baseline levels reported in REDUCE‐IT are more likely to represent a typical Western population than the baseline levels reported in JELIS, because the Japanese population has a much higher average dietary intake of oily fish compared to populations consuming a typical western diet. Together, these considerations suggest that Western patients may require higher doses of EPA, such as those used in the REDUCE‐IT trial, to achieve meaningful reductions in CV event rates.

As already discussed, some of the beneficial effects of omega‐3 PUFAs, including their TG‐lowering effects, require comparatively high doses. Thus, it is likely that patients in the icosapent ethyl arm of REDUCE‐IT experienced a greater absolute reduction in TG levels during treatment as compared to other omega‐3 PUFA trials. However, the trial investigators reported that reduction in the primary endpoint or key secondary endpoint in REDUCE‐IT did not depend on whether patients achieved TG levels below or above 150 mg/dL at 1 year.[1](#clc23220-bib-0001){ref-type="ref"} This finding provides further evidence that biological effects beyond TG lowering contributed to the clinical benefits of icosapent ethyl in the REDUCE‐IT trial. More detailed analyses and perhaps additional clinical studies may be required to establish the dose‐dependence and biological mechanisms by which icosapent ethyl reduced the rates of major CV events.

Finally, it must be noted that icosapent ethyl is a pure, esterified form of EPA, and it was used in two of the three successful trials summarized in Table [1](#clc23220-tbl-0001){ref-type="table"} (JELIS and REDUCE‐IT). Most other trials used formulations combining EPA and DHA in various concentrations. It is unknown to what degree these differences in drug formulation account for some of the inconsistencies in CV outcomes across trials. Although EPA and DHA share many biological effects, some differences have been reported.[54](#clc23220-bib-0054){ref-type="ref"}, [55](#clc23220-bib-0055){ref-type="ref"} The ongoing STRENGTH trial (NCT02104817), which uses a combination of EPA and DHA, may help to clarify the roles of omega‐3 PUFAs for secondary prevention of CV events.[82](#clc23220-bib-0082){ref-type="ref"}

5. MECHANISM OF CLINICAL BENEFIT IN REDUCE‐IT {#clc23220-sec-0009}
=============================================

With several lines of evidence suggesting that elevated TG levels are a marker of the potential for secondary prevention patients to benefit from omega‐3 PUFAs, and with the now‐established role of elevated TG levels in increased CV risk, it is tempting to assume that the TG‐lowering effect of icosapent ethyl explains its CV benefits. Indeed, icosapent ethyl is already approved in the United States for reducing TG levels in patients with very high TG levels (≥500 mg/dL).[83](#clc23220-bib-0083){ref-type="ref"}, [84](#clc23220-bib-0084){ref-type="ref"} REDUCE‐IT, however, examined people with minimum baseline TG levels as low as 135 to 150 mg/dL. And it revealed evidence that TG lowering may not fully explain CV benefits of icosapent ethyl.[1](#clc23220-bib-0001){ref-type="ref"} First, the hazard ratio for the primary endpoint associated with icosapent ethyl vs placebo was similar in subgroups defined by baseline TG levels, regardless of whether the cutoffs were 150 or 200 mg/dL. Second, the benefits of treatment were not influenced by whether patients achieved TG levels \<150 mg/dL during treatment.[1](#clc23220-bib-0001){ref-type="ref"} Although more detailed analyses are needed, the currently available analyses support the conclusion that TG lowering is not the sole mechanism responsible for lowering CV risk among the patients who participated in REDUCE‐IT. A similar conclusion was found in a post hoc analysis of the JELIS trial.[85](#clc23220-bib-0085){ref-type="ref"}

Previous trials of icosapent ethyl in patients with high TG levels (≥200 mg/dL) found that treatment led to improvements in levels of several atherogenic lipid particles and biomarkers, including apolipoprotein B, very low density lipoprotein cholesterol, lipoprotein‐associated phospholipase A2, remnant‐like particle cholesterol, and apolipoprotein C‐III.[53](#clc23220-bib-0053){ref-type="ref"}, [86](#clc23220-bib-0086){ref-type="ref"}, [87](#clc23220-bib-0087){ref-type="ref"} Furthermore, preclinical studies have described several other beneficial effects of omega‐3 PUFAs that could translate into reductions in rates of clinical events---effects such as improving endothelial function and nitric oxide availability, reducing inflammatory cytokines and enzymes, reducing activation of platelets, and contributing to plaque stabilization (summarized in Ganda et al.[5](#clc23220-bib-0005){ref-type="ref"}).

6. CONCLUSION {#clc23220-sec-0010}
=============

The REDUCE‐IT trial found that icosapent ethyl (4 g per day), a pure and stable form of the omega‐3 PUFA EPA, significantly reduced residual risk of cardiovascular events in patients with ASCVD and elevated TG levels (≥150 mg/dL) who were receiving a stable dose of statin at study entry. On superficial examination, the REDUCE‐IT trial appears to be an outlier among trials of omega‐3 PUFAs for secondary prevention of CV events. On closer inspection, however, its design and outcomes are consistent with lessons learned from previous studies. Baseline TG levels appear to be a marker of increased likelihood of benefiting from icosapent ethyl treatment, and treatment significantly lowers TG levels. However, currently available analyses suggest that reduction in TG levels likely do not fully account for the beneficial effects of treatment. Despite persistent questions regarding its full mechanism of action, icosapent ethyl significantly ameliorates residual CV risk in patients with ASCVD receiving statin therapy and has been associated with minimal adverse effects. It appears, therefore, that with the results of the REDUCE‐IT trial, we have rounded the corner; we now have in our sights the ability to further reduce the risk of CV events in appropriately selected patients with residual CV risk on optimal statin therapy.
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